{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:10Z","timestamp":1761901630251,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.msard.2020.102353","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T03:02:28Z","timestamp":1593745348000},"page":"102353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources."],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0540","authenticated-orcid":false,"given":"S.","family":"Viswanathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102353_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102249","article-title":"Current and Emerging Therapeutics for Neuromyelitis Optica Spec- trum Disorder: relevance to the COVID-19 Pandemic","author":"Abboud","year":"2020","journal-title":"Mult, Scler Relat, Disord,"},{"issue":"1","key":"10.1016\/j.msard.2020.102353_bib0002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40249-020-00646-x","article-title":"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review","volume":"9","author":"Adhikari","year":"2020","journal-title":"Infect, Dis, Poverty"},{"key":"10.1016\/j.msard.2020.102353_bib0003","unstructured":"Azathioprine, leflunomide, mercatopurine, and methotrexate, drug monitoring in primary care during COVID-19. Specialist Pharmacy Services. Published 31.3.20. Updated 9.4.20 Accessed 16.4.20 (2020). https:\/\/www.sps.nhs.uk\/articles\/dmard-drug-monitoring-in-primary-care-during-covid-19\/."},{"key":"10.1016\/j.msard.2020.102353_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102174","article-title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","volume":"43","author":"Baker","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102353_bib0005","article-title":"Consensus Statement on Immune modulation in Multiple Sclerosis and related disorders during Covid-19 pandemic:expert Group on Behalf of the Indian Academy of Neurology","author":"Bhatia","year":"2020","journal-title":"AIAN"},{"issue":"5","key":"10.1016\/j.msard.2020.102353_bib0006","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10072-020-04391-9","article-title":"Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic","volume":"41","author":"Bonavita","year":"2020","journal-title":"Neuro Sci"},{"key":"10.1016\/j.msard.2020.102353_bib0007","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","author":"Brownlee","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102353_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102282","article-title":"COVID-19 prevention and multiple sclerosis management: the SAFE pathway for the post-peak","author":"Buonomo","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102353_bib0009","article-title":"Active monitoring of persons exposed to patients with confirmed COVID-19 \u2014 United States, January\u2013February 2020","author":"Burke","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.msard.2020.102353_bib0010","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunologic features in severe and moderate coronavirus disease 2019","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2020.102353_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102204","article-title":"COVID- 19 pandemic: the experience of a multiple sclerosis centre in Chile","author":"Ciampi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102353_bib0012","unstructured":"ABN guidance on the use of Disease modifying therapies in Multiple Sclerosis in response to the threat of a corona virus epidemic. Coles A., Lim M., Giovannoni G., Anderson P.https:\/\/www.theabn.org\/news\/492925\/ABN-guidance-on-COVID19-and-MS-therapies.htm."},{"key":"10.1016\/j.msard.2020.102353_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/lt.25756","article-title":"Coronaviruses and immunosuppressed patients. The facts during the third epidemic","author":"D'Antiga","year":"2020","journal-title":"Liver Transpl."},{"issue":"10227","key":"10.1016\/j.msard.2020.102353_bib0014","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(20)30424-4","article-title":"Telemedicine 2020 and the next decade","volume":"395","author":"Dorsey","year":"2020","journal-title":"Lancet"},{"year":"2020","series-title":"Telemedicine and COVID-19:Implementation Guide","author":"Evans","key":"10.1016\/j.msard.2020.102353_bib0015"},{"key":"10.1016\/j.msard.2020.102353_bib0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2471\/BLT.17.194514","article-title":"Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection","volume":"96","author":"Fitzner","year":"2018","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.msard.2020.102353_bib0017","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMe2009758","article-title":"Asymptomatic Transmission, the Achilles\u2019 Heel of Current Strategies to Control Covid-19","volume":"382","author":"Gandhi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102353_bib0018","doi-asserted-by":"crossref","unstructured":"Giovannoni G., et\u00a0al., The COVID-19 pandemic and the use of MS disease-modifying therapies Multiple Sclerosis and Related Disorders, doi:10.1016\/j.msard.2020.102073.","DOI":"10.1016\/j.msard.2020.102073"},{"key":"10.1016\/j.msard.2020.102353_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102135","article-title":"Anti-CD20 Immunosuppressive Disease-Modifying Therapies and COVID-19","volume":"41","author":"Giovannoni","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102353_bib0020","unstructured":"Guthy Jackson Charitable Foundation (2020) Website: www.guthyjacksonfoundation.org."},{"issue":"Issue 3","key":"10.1016\/j.msard.2020.102353_bib0021","article-title":"Teriflunomide for multiple sclerosis","author":"He","year":"2016","journal-title":"Cochrane Databse of Systematic Reviews"},{"key":"10.1016\/j.msard.2020.102353_bib0022","article-title":"Telehealth: helping Your Patients and Practice Survive and Thrive During the COVID-19 Crisis with Rapid Quality Implementation","author":"Lee","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.msard.2020.102353_bib0023","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1212\/CPJ.0000000000000434","article-title":"Effectiveness of alternative dose fingolimod for multiple sclerosis","volume":"8","author":"Longbrake","year":"2018","journal-title":"Neurology. Clinical Practice."},{"issue":"1","key":"10.1016\/j.msard.2020.102353_bib0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","article-title":"Efficacy of intravenous immunoglobulin in neurological diseases","volume":"13","author":"L\u00fcnemann","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2020.102353_bib0025","doi-asserted-by":"crossref","unstructured":"Maghzi A.H., Houtchens M.K., Preziosa P. et\u00a0al. (2020). Covid-19 in Teriflunomide treated patients with multiple sclerosis. J. Neurol. doi:10.1007\/s00415-020-09944-8.","DOI":"10.21203\/rs.3.rs-28699\/v1"},{"key":"10.1016\/j.msard.2020.102353_bib0026","unstructured":"Malaysian Clinical Practice Guidelines on Management of Multiple Sclerosis Version 1 2015."},{"year":"1997","series-title":"Blueprint: Leading health Care Into the Information Age","key":"10.1016\/j.msard.2020.102353_bib0027"},{"issue":"44","key":"10.1016\/j.msard.2020.102353_bib0028","article-title":"Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab","author":"Mat\u00edas-Guiu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102353_bib0029","article-title":"Rapidly Converting to \u201cVirtual Practices\u201d: outpatient Care in the Era of Covid-19","volume":"Vol No 1","author":"Mehrotra","year":"2020","journal-title":"NEJM catalyst"},{"key":"10.1016\/j.msard.2020.102353_bib0030","unstructured":"Ministry of Health Malaysiae-portal:moh.gov.my>ncov 2019."},{"key":"10.1016\/j.msard.2020.102353_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102185","article-title":"Anti-CD20 and Covid-19 in Multiple Sclerosis and related disorders: a case series of 60 patients from Madrid, Spain","author":"Montero-Escribano","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102353_bib0032","unstructured":"Multiple Sclerosis International Federation (2020). Global COVID-19 advice for people with MS. Available onlinehttps:\/\/www.msif.org\/. Accessed March 26 2020."},{"key":"10.1016\/j.msard.2020.102353_bib0033","unstructured":"National MS Society (2020): https:\/\/www.nationalmssociety.org\/What-you-need-to-know-about-Coronavirus-(COVID-19)\/DMT-Guidelines-for-Coronavirus-(COVID-19)."},{"year":"2020","series-title":"Vital surveillances: the Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)\u2014China","key":"10.1016\/j.msard.2020.102353_bib0034"},{"key":"10.1016\/j.msard.2020.102353_bib0035","first-page":"336","article-title":"Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: a meta-analysis","volume":"30","author":"Olyaeemanesh","year":"2016","journal-title":"Med J Islam Repub Iran"},{"key":"10.1016\/j.msard.2020.102353_bib0036","first-page":"xx","article-title":"Clinical efficacy and safety of single course rituximab as induction therapy for aggressive neuromyelitis optica spectrum disorder in a resource limited center: a preliminary study","volume":"7","author":"Ong","year":"2020","journal-title":"Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.msard.2020.102353_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.05.001","article-title":"Comparison of telemedicine versus in-person visits for persons with multiple sclerosis: a randomized crossover study of feasibility, cost, and satisfaction","volume":"36","author":"Robb","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"20","key":"10.1016\/j.msard.2020.102353_bib0038","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.msard.2020.102353_bib0039","article-title":"An Italian programme for COVID-19 infection in multiple sclerosis","volume":"S1474-4422","author":"Sormani","year":"2020","journal-title":"Lancet Neurol"},{"year":"2018","series-title":"Off-Label Use of Intravenous Immunoglobulin For Neurological Conditions: A Review of Clinical Effectiveness [Internet]","author":"Sutton","key":"10.1016\/j.msard.2020.102353_bib0040"},{"key":"10.1016\/j.msard.2020.102353_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.04.021","article-title":"Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease","volume":"32","author":"Tsantes","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2020.102353_bib0042","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1352458518797290","article-title":"A Call for more research and global collaboration in South East Asia to address the challenges o DMT access and MS management in the region","volume":"25","author":"Vijayasingham","year":"2019","journal-title":"Multi Scler"},{"key":"10.1016\/j.msard.2020.102353_bib0043","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","volume":"282","author":"Viswanathan","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.msard.2020.102353_bib0044","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-020-09822-3","article-title":"Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19\/SARS-CoV-2","author":"Willis","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.msard.2020.102353_bib0045","unstructured":"World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 February 2020 [Internet]. Geneva: World Health Organization; 2020https:\/\/www.who.int\/docs\/defaultsource\/coronaviruses\/who-china-joint-mission-on-covid-19-final-report.pdf."},{"key":"10.1016\/j.msard.2020.102353_bib0046","unstructured":"Worldometer: 2020. www.worldometers.info."},{"key":"10.1016\/j.msard.2020.102353_bib0047","article-title":"Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"42","author":"Young","year":"2020","journal-title":"MSRAD"},{"key":"10.1016\/j.msard.2020.102353_bib0048","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:59Z","timestamp":1761900719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820304284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":48,"alternative-id":["S2211034820304284"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102353","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources.","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102353"}}